{"id":43676,"date":"2026-03-19T13:44:11","date_gmt":"2026-03-19T13:44:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/43676\/"},"modified":"2026-03-19T13:44:11","modified_gmt":"2026-03-19T13:44:11","slug":"novo-nordisk-patent-expiry-opens-door-to-cheaper-weight-loss-drugs-in-india-3","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/43676\/","title":{"rendered":"Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India"},"content":{"rendered":"<p>India\u2019s market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk\u2019s (NOVOb.CO)\u00a0patent on semaglutide expires this week, triggering a \u200bwave of cheaper generics from local drugmakers and worries about uneven oversight in an overcrowded market.<\/p>\n<p>\u00a0<\/p>\n<p>More than 40 Indian firms are expected to launch \u200cover 50 brands within weeks, analysts and doctors said, widening access in a price-sensitive market, but also raising concerns about misuse and confusion among prescribers as costs fall sharply.<\/p>\n<p>\u00a0<\/p>\n<p>Sun Pharma (SUN.NS)\u00a0Mankind Pharma (MNKI.NS), Dr. Reddy\u2019s (REDY.NS), Zydus (ZYDU.NS), Lupin (LUPN.NS),\u00a0and Alkem (ALKE.NS), opens new tab are among the companies expected to launch generic versions of semaglutide, the active ingredient in Novo\u2019s diabetes drug Ozempic and weight-loss treatment Wegovy.<\/p>\n<p>\u00a0<\/p>\n<p>\u201cWith high demand, \u200bfalling prices and multiple brands, you may see direct pharmacy purchases, distributor-level leakages, or cosmetic or lifestyle use especially in urban markets,\u201d said Salil \u200bKallianpur, an independent analyst.<\/p>\n<p>\u00a0<\/p>\n<p>\u201cThis could lead to misuse, poor titration and unmanaged side effects and eventually regulatory tightening.\u201d<\/p>\n<p>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"India\u2019s market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk\u2019s (NOVOb.CO)\u00a0patent&hellip;\n","protected":false},"author":2,"featured_media":43677,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[15786,15789,565,272,357,6804,15790,689,277],"class_list":{"0":"post-43676","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-diabetes","9":"tag-drug-pricing","10":"tag-india","11":"tag-novo-nordisk","12":"tag-obesity","13":"tag-patents","14":"tag-patient-access","15":"tag-semaglutide","16":"tag-weight-loss-drugs"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116256143005326456","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/43676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=43676"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/43676\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/43677"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=43676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=43676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=43676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}